Endovascular Engineering Presents Positive Results from ENGULF Feasibility Trial with its Hēlo™ PE Thrombectomy System for the Treatment of Pulmonary Embolism

MENLO PARK, Calif., May 6, 2024 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a pioneering medical device company at the forefront of advancing clot removal technologies for venous thromboembolism (VTE), proudly announced positive safety and feasibility results from its ENGULF US…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks